Wednesday - September 17, 2025
Tagrisso Plus Chemotherapy Demonstrated a Median Overall Survival of Nearly Four Years, the Longest Benefit Ever Reported in a Global Phase III Trial in EGFR-Mutated Advanced Lung Cancer
September 09, 2025
WILMINGTON, Delaware, Sept. 9 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

TAGRISSO (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

FLAURA2 final overall survival analysis reinforces thefavorable benefit-risk profile of this combination

Results underscore TAGRISS . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products